Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-BCMA CAR-iNK
- Development stage
- Preclinical
- Lead developer
- Cell Inspire Biotechnology
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
anti-BCMA CAR-iNK is an experimental allogeneic cell therapy composed of natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs) and engineered to express a chimeric antigen receptor (CAR) specific for B-cell maturation antigen (BCMA). Developed by Cell Inspire Biotechnology and partners, the therapy utilizes a non-viral piggybac transposon system to transduce iPSCs, which are then differentiated into highly pure NK cells (CD45+/CD56+). These CAR-iNK cells are designed to provide an off-the-shelf treatment for multiple myeloma, combining the targeted specificity of CAR-T therapies with the safety and scalability of iPSC-derived NK cells. Preclinical data presented at ASH 2023 demonstrated that these cells exhibit potent, dose-dependent cytotoxicity against BCMA-expressing myeloma cell lines such as NCI-H929 and OPM-2, although they were noted to be less efficient than GPRC5D-targeted counterparts in certain models.
- Other names
- BCMA CAR-iNKanti-BCMA CAR-iPSC-NK
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on anti-BCMA CAR-iNK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-BCMA CAR-iNK.